216 related articles for article (PubMed ID: 23885033)
1. Meningococcal polysaccharide A O-acetylation levels do not impact the immunogenicity of the quadrivalent meningococcal tetanus toxoid conjugate vaccine: results from a randomized, controlled phase III study of healthy adults aged 18 to 25 years.
Lupisan S; Limkittikul K; Sosa N; Chanthavanich P; Bianco V; Baine Y; Van der Wielen M; Miller JM
Clin Vaccine Immunol; 2013 Oct; 20(10):1499-507. PubMed ID: 23885033
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
Klein NP; Habanec T; Kosina P; Shah NR; Kolhe D; Miller JM; Hezareh M; Van der Wielen M
Vaccine; 2018 Apr; 36(17):2356-2363. PubMed ID: 29576307
[TBL] [Abstract][Full Text] [Related]
3. The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiority study.
Dbaibo G; Macalalad N; Aplasca-De Los Reyes MR; Dimaano E; Bianco V; Baine Y; Miller J
Hum Vaccin Immunother; 2012 Jul; 8(7):873-80. PubMed ID: 22485050
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.
Dbaibo G; El-Ayoubi N; Ghanem S; Hajar F; Bianco V; Miller JM; Mesaros N
Drugs Aging; 2013 May; 30(5):309-19. PubMed ID: 23494214
[TBL] [Abstract][Full Text] [Related]
5. Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents.
Quiambao BP; Jain H; Bavdekar A; Dubey AP; Kolhe D; Bianco V; Van der Wielen M; Miller JM
Hum Vaccin Immunother; 2016 Aug; 12(8):2162-2168. PubMed ID: 27152501
[TBL] [Abstract][Full Text] [Related]
6. Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.
Borja-Tabora CF; Montalban C; Memish ZA; Boutriau D; Kolhe D; Miller JM; Van der Wielen M
BMC Infect Dis; 2015 Oct; 15():409. PubMed ID: 26437712
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and Safety of Investigational MenABCWY Vaccine and of 4CMenB and MenACWY Vaccines Administered Concomitantly or Alone: a Phase 2 Randomized Study of Adolescents and Young Adults.
Beran J; Dražan D; Enweonye I; Bhusal C; Toneatto D
mSphere; 2021 Dec; 6(6):e0055321. PubMed ID: 34787449
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study.
Rivera L; Schwarz TF; Kim KH; Kim YK; Behre U; Cha SH; Jo DS; Lee J; Lee JS; Cheuvart B; Jastorff A; Van der Wielen M
Vaccine; 2018 Jul; 36(31):4750-4758. PubMed ID: 29960800
[TBL] [Abstract][Full Text] [Related]
9. A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years.
Vesikari T; Forstén A; Boutriau D; Bianco V; Van der Wielen M; Miller JM
Hum Vaccin Immunother; 2012 Dec; 8(12):1882-91. PubMed ID: 23032168
[TBL] [Abstract][Full Text] [Related]
10. Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine.
Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM
Hum Vaccin Immunother; 2016; 12(1):132-9. PubMed ID: 26575983
[TBL] [Abstract][Full Text] [Related]
11. Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study.
Borja-Tabora C; Montalban C; Memish ZA; Van der Wielen M; Bianco V; Boutriau D; Miller J
BMC Infect Dis; 2013 Mar; 13():116. PubMed ID: 23510357
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults.
Bermal N; Huang LM; Dubey AP; Jain H; Bavdekar A; Lin TY; Bianco V; Baine Y; Miller JM
Hum Vaccin; 2011 Feb; 7(2):239-47. PubMed ID: 21343698
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM
Pediatr Infect Dis J; 2015 Dec; 34(12):e298-307. PubMed ID: 26780033
[TBL] [Abstract][Full Text] [Related]
14. The investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults.
Aplasca-De Los Reyes MR; Dimaano E; Macalalad N; Dbaibo G; Bianco V; Baine Y; Miller J
Hum Vaccin Immunother; 2012 Jul; 8(7):881-7. PubMed ID: 22485048
[TBL] [Abstract][Full Text] [Related]
15. Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents.
Quiambao BP; Bavdekar A; Dubey AP; Jain H; Kolhe D; Bianco V; Miller JM; Van der Wielen M
Hum Vaccin Immunother; 2017 Mar; 13(3):636-644. PubMed ID: 28152332
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccine.
Quiambao B; Peyrani P; Li P; Cutler MW; Van Der Wielen M; Perez JL; Webber C
Hum Vaccin Immunother; 2020 Jun; 16(6):1272-1279. PubMed ID: 32401600
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study.
Cutland CL; Nolan T; Halperin SA; Kurugol Z; Ahmed K; Perrett KP; Richmond P; Marshall HS; Ceyhan M; Kolhe D; Hezareh M; Van Der Wielen M
Vaccine; 2018 Mar; 36(14):1908-1916. PubMed ID: 29503112
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study.
Dbaibo G; Tinoco Favila JC; Traskine M; Jastorff A; Van der Wielen M
Vaccine; 2018 Jun; 36(28):4102-4111. PubMed ID: 29784470
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers.
Nolan T; Booy R; Marshall HS; Richmond P; Nissen M; Ziegler JB; Baine Y; Traskine M; Jastorff A; Van der Wielen M
Pediatr Infect Dis J; 2019 Jun; 38(6):643-650. PubMed ID: 31116180
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trial.
Macias Parra M; Gentile A; Vazquez Narvaez JA; Capdevila A; Minguez A; Carrascal M; Willemsen A; Bhusal C; Toneatto D
Vaccine; 2018 Nov; 36(50):7609-7617. PubMed ID: 30414782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
